<--- Back to Details
First PageDocument Content
Antiandrogens / Chemistry / Clinical medicine / Enzyme inhibitors / Cancer / Prostate cancer / Organofluorides / Galeterone / Steroids / Enzalutamide / Abiraterone acetate / Medivation
Date: 2016-08-03 18:48:38
Antiandrogens
Chemistry
Clinical medicine
Enzyme inhibitors
Cancer
Prostate cancer
Organofluorides
Galeterone
Steroids
Enzalutamide
Abiraterone acetate
Medivation

Microsoft WordDOCX

Add to Reading List

Source URL: securities.stanford.edu

Download Document from Source Website

File Size: 234,17 KB

Share Document on Facebook

Similar Documents

Microsoft WordDOCX

Microsoft WordDOCX

DocID: 1rnqZ - View Document

Award ID: CP130020 Project Title: Androgen Receptor N-Terminus Blocker Program for Prostate Cancer Award Mechanism: Company Relocation

Award ID: CP130020 Project Title: Androgen Receptor N-Terminus Blocker Program for Prostate Cancer Award Mechanism: Company Relocation

DocID: 19pfm - View Document

September 10, 2012  Astex Pharmaceuticals Announces Initiation of HSP90 Inhibitor AT13387 Clinical Trial in Prostate Cancer Patients DUBLIN, Calif., Sept. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:

September 10, 2012 Astex Pharmaceuticals Announces Initiation of HSP90 Inhibitor AT13387 Clinical Trial in Prostate Cancer Patients DUBLIN, Calif., Sept. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:

DocID: 11qq3 - View Document

Microsoft PowerPointGU Disease Site Schema Flowsheet.pptx

Microsoft PowerPointGU Disease Site Schema Flowsheet.pptx

DocID: W9oO - View Document

R&D Pipeline (October[removed]Global Development (1) Approval / Labeling Revision #Compounds with

R&D Pipeline (October[removed]Global Development (1) Approval / Labeling Revision #Compounds with "In-house" in this column include one discovered by collaborative research. (The same applicable hereafter.) Code No. Gen

DocID: IFu7 - View Document